{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T16:30:23Z","timestamp":1789317023594,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["AdG2019-884796"],"award-info":[{"award-number":["AdG2019-884796"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Dutch Research Council","doi-asserted-by":"publisher","award":["09150172010067"],"award-info":[{"award-number":["09150172010067"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["777357"],"award-info":[{"award-number":["777357"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM18055-5GF"],"award-info":[{"award-number":["LSHM18055-5GF"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","award":["LSHM22042-SFG"],"award-info":[{"award-number":["LSHM22042-SFG"]}],"id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022115","name":"Dutch Arthritis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022115","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ard.2026.03.016","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T17:30:12Z","timestamp":1776015012000},"page":"1625-1636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topoisomerase 1-DNA complexes are preferentially recognised by a subset of anti-topoisomerase 1 autoantibodies and their corresponding B cell receptors in systemic sclerosis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9582-2837","authenticated-orcid":false,"given":"Sam","family":"Neppelenbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrie M.","family":"Wortel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danique M.H.","family":"van Rijswijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein J.A.L.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert Q.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki M.","family":"Loof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Erb\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.W. Nivine","family":"Levarht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Everts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert J.R.","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeska K.","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Fehres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 E.M.","family":"Toes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5700-5617","authenticated-orcid":false,"given":"Hans U.","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2026.03.016_bib0001","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.03.016_bib0002","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/art.42863","article-title":"Unique interplay between antinuclear antibodies and nuclear molecules in the pathogenesis of systemic lupus erythematosus","volume":"76","author":"Pisetsky","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.03.016_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152136","article-title":"Autoreactive B cell responses targeting nuclear antigens in systemic sclerosis: implications for disease pathogenesis","volume":"58","author":"Liem","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.03.016_bib0004","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","article-title":"Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature","volume":"21","author":"Pokeerbux","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.03.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001694","article-title":"All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019","volume":"7","author":"Bournia","year":"2021","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.03.016_bib0006","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.03.016_bib0007","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003148","article-title":"Anti-topoisomerase, but not anti-centromere B cell responses in systemic sclerosis display active, Ig-secreting cells associated with lung fibrosis","volume":"9","author":"Wortel","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.03.016_bib0008","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/art.41403","article-title":"Association of anti-topoisomerase I antibodies of the IgM isotype with disease progression in anti-topoisomerase I-positive systemic sclerosis","volume":"72","author":"Boonstra","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.03.016_bib0009","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.016_bib0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.03.016_bib0011","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/art.33484","article-title":"Heparin inhibits the interaction of DNA topoisomerase I\/anti-topoisomerase I immune complexes with heparan sulfate on dermal fibroblasts","volume":"64","author":"Arcand","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.03.016_bib0012","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.21646","article-title":"DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients","volume":"54","author":"H\u00e9nault","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.03.016_bib0013","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1002\/art.20515","article-title":"Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis","volume":"50","author":"H\u00e9nault","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2026.03.016_bib0014","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41584-019-0211-0","article-title":"B cell checkpoints in autoimmune rheumatic diseases","volume":"15","author":"Rubin","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ard.2026.03.016_bib0015","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41590-019-0427-9","article-title":"B cell signaling in context","volume":"20","author":"Kwak","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0016","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1172\/JCI78084","article-title":"Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity","volume":"125","author":"Suurmond","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ard.2026.03.016_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molimm.2012.06.001","article-title":"Structural analysis of B-cell epitopes in antibody:protein complexes","volume":"53","author":"Kringelum","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0018","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ard.2026.03.016_bib0019","doi-asserted-by":"crossref","first-page":"23200","DOI":"10.1074\/jbc.M801146200","article-title":"Topoisomerase I requirement for death receptor-induced apoptotic nuclear fission","volume":"283","author":"Sordet","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ard.2026.03.016_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000159","article-title":"Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis","volume":"2","author":"Meijs","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.03.016_bib0021","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1039\/C5NR01474C","article-title":"Real-time investigation of human topoisomerase I reaction kinetics using an optical sensor: a fast method for drug screening and determination of active enzyme concentrations","volume":"7","author":"Kristoffersen","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.ard.2026.03.016_bib0022","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/annrheumdis-2019-216499","article-title":"Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications","volume":"79","author":"Kissel","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.016_bib0023","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/rheumatology\/keac549","article-title":"Functional autoantibodies in systemic sclerosis: influence of autologous stem cell transplantation and correlation with clinical outcome","volume":"62","author":"Bankamp","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.03.016_bib0024","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0014-5793(86)81117-6","article-title":"Inhibition of topoisomerase I by antibodies in sera from scleroderma patients","volume":"209","author":"Samuels","year":"1986","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ard.2026.03.016_bib0025","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond binding: antibody effector functions in infectious diseases","volume":"18","author":"Lu","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0026","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0027","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.4049\/jimmunol.169.6.3321","article-title":"Activation of monocytic cells through Fc gamma receptors induces the expression of macrophage-inflammatory protein (MIP)-1 alpha, MIP-1 beta, and RANTES","volume":"169","author":"Fern\u00e1ndez","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0028","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.4049\/jimmunol.155.6.3161","article-title":"Monocyte Fc gamma receptor cross-linking induces IL-8 production","volume":"155","author":"Marsh","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0029","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.imbio.2014.07.016","article-title":"Fc\u03b3RIIa cross-talk with TLRs, IL-1R, and IFN\u03b3R selectively modulates cytokine production in human myeloid cells","volume":"220","author":"Vogelpoel","year":"2015","journal-title":"Immunobiology"},{"key":"10.1016\/j.ard.2026.03.016_bib0030","doi-asserted-by":"crossref","first-page":"eabf8654","DOI":"10.1126\/scitranslmed.abf8654","article-title":"High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages","volume":"13","author":"Hoepel","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ard.2026.03.016_bib0031","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0032","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jneuroim.2015.12.016","article-title":"Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity","volume":"291","author":"Huijbers","year":"2016","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.ard.2026.03.016_bib0033","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1136\/annrheumdis-2016-209297","article-title":"Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs","volume":"76","author":"Figueiredo","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.03.016_bib0034","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2665-9913(20)30381-7","article-title":"The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study","volume":"3","author":"Nijjar","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.03.016_bib0035","doi-asserted-by":"crossref","first-page":"186ra65","DOI":"10.1126\/scitranslmed.3005370","article-title":"Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity","volume":"5","author":"Darrah","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ard.2026.03.016_bib0036","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1182\/blood-2008-10-185421","article-title":"BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation","volume":"113","author":"Eckl-Dorna","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ard.2026.03.016_bib0037","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/ncomms1769","article-title":"BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-\u03baB pathway","volume":"3","author":"Pone","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.ard.2026.03.016_bib0038","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1074-7613(03)00323-6","article-title":"Activation of autoreactive B cells by CpG dsDNA","volume":"19","author":"Viglianti","year":"2003","journal-title":"Immunity"},{"key":"10.1016\/j.ard.2026.03.016_bib0039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08916934.2014.993027","article-title":"B cell TLR1\/2, TLR4, TLR7 and TLR9 interact in induction of class switch DNA recombination: modulation by BCR and CD40, and relevance to T-independent antibody responses","volume":"48","author":"Pone","year":"2015","journal-title":"Autoimmunity"},{"key":"10.1016\/j.ard.2026.03.016_bib0040","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1073\/pnas.1031537100","article-title":"DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein","volume":"100","author":"Carey","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ard.2026.03.016_bib0041","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41467-021-27686-7","article-title":"Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states","volume":"13","author":"Takahashi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ard.2026.03.016_bib0042","doi-asserted-by":"crossref","first-page":"13767","DOI":"10.1073\/pnas.2235886100","article-title":"Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality","volume":"100","author":"Woo","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ard.2026.03.016_bib0043","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/ar3435","article-title":"Decreased catalytic function with altered SUMOylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts","volume":"13","author":"Zhou","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ard.2026.03.016_bib0044","doi-asserted-by":"crossref","first-page":"eaba6290","DOI":"10.1126\/sciadv.aba6290","article-title":"A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation","volume":"6","author":"Sun","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.ard.2026.03.016_bib0045","doi-asserted-by":"crossref","first-page":"e250","DOI":"10.1002\/cpz1.250","article-title":"Topoisomerase assays","volume":"1","author":"Nitiss","year":"2021","journal-title":"Curr Protoc."},{"key":"10.1016\/j.ard.2026.03.016_bib0046","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06116","article-title":"Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide","volume":"449","author":"Lande","year":"2007","journal-title":"Nature"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726002025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T12:25:59Z","timestamp":1786191959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726002025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0003496726002025"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.016","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topoisomerase 1-DNA complexes are preferentially recognised by a subset of anti-topoisomerase 1 autoantibodies and their corresponding B cell receptors in systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}